Repligen (RGEN) director granted RSUs and options in Form 4 filing
Rhea-AI Filing Summary
Repligen Corporation director Martin D. Madaus reported equity awards, not open-market trades. He received 995 restricted stock units, each representing one share of common stock. These units vest on the earlier of May 14, 2027, one year from grant, or the next annual shareholder meeting, and settlement has been deferred until after his board service ends.
He was also granted stock options on 2,239 shares at an exercise price of $103.38 per share, vesting on the same schedule and expiring on May 14, 2036. Following these awards, he directly holds 6,581 common shares and indirectly holds additional shares through a spouse trust with 11 shares and a 2011 revocable trust with 1,800 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 995 shares
Net Buy
4 txns
Insider
Madaus Martin D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 2,239 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 995 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,239 shares (Direct);
Common Stock — 6,581 shares (Direct);
Common Stock — 1,800 shares (Indirect, By Martin D. Madaus 2011 Revocable Trust);
Common Stock — 11 shares (Indirect, Spouse Trust)
Footnotes (2)
- F1. Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
- F2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Key Figures
Restricted stock units granted: 995 units
Stock options granted: 2,239 options
Option exercise price: $103.38 per share
+5 more
8 metrics
Restricted stock units granted
995 units
Award to director; each unit equals one common share
Stock options granted
2,239 options
Right to buy Repligen common stock
Option exercise price
$103.38 per share
Stock option grant on May 14, 2026
Option expiration date
May 14, 2036
Final date to exercise options if vested
Direct shares after transaction
6,581 shares
Common stock directly owned by Madaus
Indirect spouse trust holdings
11 shares
Common stock held via spouse trust
Indirect revocable trust holdings
1,800 shares
Held by Martin D. Madaus 2011 Revocable Trust
RSU vesting date trigger
May 14, 2027 or next annual meeting
Earlier date controls vesting for RSUs and options
Key Terms
restricted stock units, contingent right to receive one share, Deferred Compensation Plan for Non-Employee Directors, separation of the Reporting Person's service as a Director, +1 more
5 terms
restricted stock units financial
"Mr. Madaus was awarded 995 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Deferred Compensation Plan for Non-Employee Directors financial
"The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors."
separation of the Reporting Person's service as a Director financial
"shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Repligen (RGEN) disclose in Martin D. Madaus’s latest Form 4?
Repligen reported equity awards to director Martin D. Madaus, not market trades. He received 995 restricted stock units and stock options on 2,239 shares, both vesting on the earlier of May 14, 2027 or the next annual shareholder meeting.
How many restricted stock units did Repligen (RGEN) grant to director Martin D. Madaus?
Repligen granted 995 restricted stock units to director Martin D. Madaus. Each unit represents a contingent right to receive one share of common stock, vesting on the earlier of May 14, 2027 or the next annual shareholder meeting, subject to his continued service.
What are the terms of Martin D. Madaus’s new Repligen (RGEN) stock options?
Madaus received stock options covering 2,239 shares of Repligen common stock. The options have a $103.38 exercise price, vest in full on the earlier of May 14, 2027 or the next annual shareholder meeting, and expire on May 14, 2036 if not exercised.
How are Martin D. Madaus’s Repligen (RGEN) restricted stock units settled?
The 995 restricted stock units may only be settled in Repligen common stock. Madaus elected to defer settlement under the Deferred Compensation Plan for Non-Employee Directors, so shares will be issued after his separation from board service, following his deferral election terms.
When do Martin D. Madaus’s Repligen (RGEN) equity awards vest?
Both the 995 restricted stock units and the 2,239-share stock option award vest in full on the earlier of May 14, 2027 or the date of the next annual shareholder meeting, which has not yet been determined, according to the Form 4 footnotes.